Head and Neck Cancer Market, [By Cancer Type (Oral or Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal, Laryngeal or Hypopharyngeal Cancer); By Diagnostic Techniques; By Treatment Type; By End Use; and Geography - Trend, Analysis and Forecast t

Head and Neck Cancer Market, [By Cancer Type (Oral or Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal, Laryngeal or Hypopharyngeal Cancer); By Diagnostic Techniques; By Treatment Type; By End Use; and Geography - Trend, Analysis and Forecast till 2032

The global head and neck cancer market size is expected treach USD 4,523.43 million by 2032, according ta new study by Polaris Market Research. The report “Head and Neck cancer Market, By Drug Class (Phosphodiestrase-4 Inhibitors, Anti-PD-1 Monoclonal Antibodies, Long-Acting Bronchodilators, Short-Acting Bronchodilators, Methylxanthines, Corticosteroids), By COPD Type; By Treatment Type: By Distribution Channel: By Region; Segment Forecast, 2023 - 2032” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.

The head and neck cancer industry is expected tgrow at the quickest rate over the forecast period owing tincreasing global alcohol and tobacco-consuming consumers and the geriatric population.

Head and neck cancer disorders are generally characterized by cancer in the squamous cells present in the lining of the mouth, voice box (larynx), and throat (pharynx). The disorder can alsbe found in various parts such as sinuses, salivary glands, and muscles or nerves.

Head and neck cancer is considered the seventh most common cancer globally and contributes tmore than 8,00,000 new cases annually, as per the National library of medicine. As per the National Institute of Cancer, the major reasons for head and neck cancer disorder can be attributed tcontinuous alcohol and tobaccuse, infection with cancer-causing human papillomavirus, occupational exposure, radiation exposure, and other underlying genetic condition. Common symptoms witnessed in the disorder are a lump in the neck, sore mouth, difficulty swallowing, hoarseness in the voice, white or red patches on the gums, bleeding through the nose, swelling under the chin, and numbness or paralysis of the muscles in the face.

The major restraining factors for the head and neck cancer market are expensive diagnosis therapies and the unavailability of well-developed cancer treatment clinics across underdeveloped countries.

Head and neck cancer Market Report Highlights

•The covid-19 pandemic harmed the head and neck cancer market. Factors such as limited inpatient services, fear of contact with healthcare providers, and telemedical visits during the pandemic led ta delayed diagnosis for the head and neck cancer market.

•In the drug class, the anti-PD-monoclonal antibodies segment is anticipated tdominate the market. The major factor behind the growth can be attributed tthe higher efficiency of the drug against the cancer cells. Monoclonal antibodies such as PD-1 and PD-L1 effectively target the checkpoint proteins that attack the body's cancer cells.

•In the distribution channel segment, the hospital pharmacy is anticipated tdominate the market in 2022 due tincreasing demand for cancer-treating drugs and therapies from rising admission of head and neck cancer patients in private hospitals and public hospitals globally.

In the forecast period, the North America region is projected tdominate the head and neck cancer market owing ta larger share of patients and their expenditure on treating head and neck cancer. The continuous R&D on new drugs and drugs approved by the US Food and Drug Administration (FDA) has increased the demand for more effective therapies from all over the world and further fueled the market in the region.

Polaris Market Research has segmented the Head and neck cancer Market report based on Drug class, COPD type, treatment type, distribution channel, and region:

Head and neck cancer Market, Drug class Outlook (Revenue - USD Million, 2019 - 2032)

Phosphodiestrase-4 Inhibitors

Anti-PD-1 Monoclonal Antibodies

Long-Acting Bronchodilators

Short-Acting Bronchodilators

Methylxanthines

Corticosteroids

Head and neck cancer Market, COPD Outlook (Revenue - USD Million, 2019 - 2032)

Chronic Bronchitis

Emphysema

Head and neck cancer Market, Treatment Type Outlook (Revenue - USD Million, 2019- 2032)

Drugs

Oxygen therapy

Surgery

Others

Head and neck cancer Market, Distribution Channel Outlook (Revenue - USD Million, 2019- 2032)

Hospitals Pharmacies

E-Commerce

Retail Pharmacies

Head and neck cancer Market, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa